Current Gastroenterology Reports

, 13:465

Update on the Management of Crohn’s Disease

  • Anna M. Buchner
  • Wojciech Blonski
  • Gary R. Lichtenstein
Article

DOI: 10.1007/s11894-011-0220-x

Cite this article as:
Buchner, A.M., Blonski, W. & Lichtenstein, G.R. Curr Gastroenterol Rep (2011) 13: 465. doi:10.1007/s11894-011-0220-x

Abstract

Crohn’s disease (CD) is a chronic inflammatory disorder characterized by focal, asymmetric, transmural inflammation of any part of the luminal gastrointestinal tract of uncertain etiology and an unpredictable course. The available treatment options include aminosalicylates, budesonide and systemic corticosteroids, antibiotics, immunomodulators,methotrexate and anti-TNF agents. This review discusses recent developments in the treatment of CD and provides a comprehensive update on management of patients with CD based on the data from randomized controlled trials. Pique

Key words

Crohn’s diseaseMesalamineCorticosteroidsBudesonideAzathioprine6-mercaptopurineAnti-TNF antibodiesInfliximabAdalimumabCertolizumab pegolNatalizumab

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Anna M. Buchner
    • 1
  • Wojciech Blonski
    • 1
    • 2
  • Gary R. Lichtenstein
    • 1
    • 3
  1. 1.Division of GastroenterologyUniversity of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of GastroenterologyMedical UniversityWroclawPoland
  3. 3.Gastroenterology DivisionUniversity of Pennsylvania School of Medicine, Hospital of the University of PennsylvaniaPhiladelphiaUSA